Physician profile
Bradley Christensen
NPI 1720475874
$31,110.64
in general payments reported to CMS, 2019-2025
46 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $290 · 2023: $4,479 · 2024: $11K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Consulting Fee: $5,314 · Food and Beverage: $4,721 · Travel and Lodging: $2,966 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,638.75 |
| Consulting Fee | $5,313.75 |
| Food and Beverage | $4,721.18 |
| Travel and Lodging | $2,966.27 |
| Education | $180.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $21,226.93 | 2024-2025 | Xospata |
| Sobi, INC | $2,501.15 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $1,895.33 | 2023-2025 | |
| Lilly USA, LLC | $1,139.46 | 2024-2025 | Jaypirca |
| Genzyme Corporation | $363.19 | 2022-2025 | |
| Incyte Corporation | $332.99 | 2022-2025 | Monjuvi, Jakafi, Niktimvo |
| Janssen Biotech, INC. | $281.24 | 2023-2024 | Darzalex, Tecvayli, Talvey |
| Adc Therapeutics America, INC. | $228.98 | 2022-2024 | |
| Rigel Pharmaceuticals, INC. | $219.48 | 2022-2024 | Rezlidhia, Tavalisse |
| Abbvie INC. | $198.10 | 2023-2025 | Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $193.81 | 2022-2023 | Imbruvica, Epkinly |
| Merck Sharp & Dohme LLC | $177.37 | 2024-2025 | Keytruda, Reblozyl, Welireg |
| Pfizer INC. | $174.37 | 2024 | |
| Adaptive Biotechnologies Corporation | $163.77 | 2022-2024 | Clonoseq |
| Genmab U.S., INC. | $161.23 | 2023-2025 | Epkinly |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $160.04 | 2023-2024 | Zepzelca, Vyxeos |
| Karyopharm Therapeutics INC. | $144.90 | 2023-2025 | Xpovio |
| Blueprint Medicines Corporation | $134.30 | 2022-2024 | Ayvakit |
| Glaxosmithkline, LLC. | $122.08 | 2023-2025 | Ojjaara, Shingrix |
| Morphosys, US INC. | $120.68 | 2023 | Monjuvi |
| Kite Pharma, INC. | $109.24 | 2024-2025 | Yescarta |
| Regeneron Healthcare Solutions, INC. | $100.50 | 2024-2025 | Libtayo |
| Daiichi Sankyo INC. | $96.40 | 2023-2024 | Vanflyta |
| Astrazeneca Pharmaceuticals Lp | $76.28 | 2023-2024 | Calquence |
| Geron Corporation | $73.66 | 2025 | Rytelo |
| Takeda Pharmaceuticals U.S.A., INC. | $68.94 | 2022-2024 | Iclusig |
| Servier Pharmaceuticals LLC | $67.38 | 2024 | |
| Mirati Therapeutics, INC. | $58.82 | 2023-2024 | Krazati |
| Amgen INC. | $58.58 | 2023 | Blincyto, Kyprolis, Nplate |
| Seagen INC. | $54.66 | 2023 | Adcetris |
| Legend Biotech USA INC. | $53.06 | 2024-2025 | Carvykti |
| Emmaus Medical, INC. | $48.80 | 2023-2024 | Endari |
| Exelixis INC. | $47.80 | 2025 | Cabometyx |
| Syndax Pharmaceuticals, INC. | $41.79 | 2025 | |
| Acrotech Biopharma INC. | $36.22 | 2022-2023 | Beleodaq |
| Genentech USA, INC. | $26.86 | 2023 | Polivy, Lunsumio, Columvi |
| Cti Biopharma Corp. | $24.19 | 2023 | Vonjo |
| Pharmaessentia USA Corporation | $24.12 | 2023 | Besremi |
| Recordati_rare_diseases_inc. | $19.79 | 2023 | Sylvant |
| Menarini Silicon Biosystems, INC. | $19.28 | 2024 | |
| Sanofi-Aventis U.S. LLC | $18.37 | 2023 | |
| Epizyme, INC. | $15.68 | 2022 | |
| Beigene USA, INC. | $15.66 | 2023 | Brukinsa |
| Celgene Corporation | $15.16 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Christensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.